Temporary adalimumab dose escalation is effective in Crohn's disease patients with secondary non-response

Journal of Crohn's and Colitis

Volumn 7, Issue 7, 2013, Pages

  Sutharshan, K ^a   Gearry, R B ^a,b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; MERCAPTOPURINE; METHOTREXATE;

CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG INDUCED DISEASE; FEMALE; HUMAN; INJECTION SITE REACTION; LETTER; MALE; OPEN STUDY; OSTEOMYELITIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 84878636740     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.01.002     Document Type: Letter

References (3)

1. Regueiro M., Siemanowski B., Kip K.E., Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007, 13(9):1093-1099. [Epub 2007/05/08].
2. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., Henckaerts L., Van Assche G., Vermeire S., Rutgeerts P. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009 Apr, 58(4):501-508.
3. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359(9317):1541-1549.